FDA Extends Nexplanon Use - Summary - MDSpire

FDA Extends Nexplanon Use

  • By

  • Kathryn Wighton

  • January 20, 2026

  • 3 min

Share

Objective:

To extend the labeled duration of use of the etonogestrel implant (Nexplanon) for pregnancy prevention from three years to up to five years.

Approach:
    Key Findings:
    • Nexplanon is effective for up to five years with no pregnancies reported during years 4 and 5.
    • No new safety findings were observed during the extended use.
    • Changes in menstrual bleeding patterns were the most common adverse reaction leading to discontinuation.
    Interpretation:

    The updated label for Nexplanon reflects its efficacy and safety for a broader range of women, including those with higher BMIs.

    Limitations:
    • The study was open-label and single-arm, which may introduce bias.
    • The long-term effects beyond five years are not evaluated.
    Conclusion:

    Nexplanon is now approved for pregnancy prevention for up to five years, enhancing contraceptive options for women.

    Sources:

Original Source(s)

Related Content